{"id":"https://genegraph.clinicalgenome.org/r/d762647a-d693-4ae1-a2c4-78760df7215cv1.0","type":"EvidenceStrengthAssertion","dc:description":"EIF2B4 was first reported in relation to autosomal recessive leukoencephalopathy with vanishing white matter 4 in 2002 (van der Knaap et al., PMID: 11835386). Affected individuals present with gait dysfunction, spasticity, cognitive decline, and white matter abnormalities on MRI.  Some females develop ovarian failure. Onset is variable from infancy to adulthood, and progression of disease is often in the setting of fever, trauma, or stress. Vanishing white matter disease has also been referred to as Childhood Ataxia with Central Nervous System Hypomyelination (CACH). Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found that a phenotypic spectrum exists and there is no difference in molecular mechanism or inheritance pattern. Therefore, we chose to curate this gene-disease relationship under the disease term leukoencephalopathy with vanishing white matter 4 (OMIM:620314, MONDO:0957872). \n\nEight variants (missense, nonsense, canonical) that have been reported in 8 probands in 4 publications (PMIDs: 11835386, 15136673, 14566705, 22128017) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity is reported to be loss of function. This gene-disease relationship is also supported by experimental evidence (PMIDs: 33300869, 26974157, 24532666). The zebrafish model is associated with impaired motor behavior and abnormal CNS development. The mouse model is associated with growth restriction, progressive ataxia, epileptic seizures. Protein interaction studies have shown that the subunit encoded by EIF2B4 interacts with the subunit of a previously curated gene EIF2B5.  In summary, definitive evidence supports the relationship between EIF2B4 and leukoencephalopathy with vanishing white matter 4. This has been repeatedly demonstrated in the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen Leukodystrophy and Leukoencephalopathy GCEP on the meeting date December 4, 2024 (SOP Version 11).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/d762647a-d693-4ae1-a2c4-78760df7215c","GCISnapshot":"https://genegraph.clinicalgenome.org/r/a3c95d30-0045-4bf9-8529-3c701bb1eab5","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/a3c95d30-0045-4bf9-8529-3c701bb1eab5_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10107","date":"2024-12-12T00:34:52.482Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/a3c95d30-0045-4bf9-8529-3c701bb1eab5_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10107","date":"2024-12-11T17:00:00.000Z","role":"Approver"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a3c95d30-0045-4bf9-8529-3c701bb1eab5_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a3c95d30-0045-4bf9-8529-3c701bb1eab5_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6d849a7d-1e78-4b84-85ef-343ecc3bd4ab","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9c7d3a58-1a68-4571-abfd-903fc5e84d43","type":"Finding","dc:description":"Mouse model recapitulates motor deficits and abnormal CNS development seen in human disease.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26974157","rdfs:label":"Mouse model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/bce18005-0f09-45aa-bb9b-2edb5dcb5a42","type":"EvidenceLine","dc:description":"Non-mammalian model organism.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/987c3ee8-0c16-43f6-8cfb-171460c28254","type":"Finding","dc:description":"Model recapitulates motor impairment and abnormal CNS development seen in patients with VWM.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33300869","rdfs:label":"Zebrafish model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/a3c95d30-0045-4bf9-8529-3c701bb1eab5_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cbf99747-68b1-4794-b236-13498e6ca219","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a76a6345-48e2-4336-bfc3-c117292ca36b","type":"Finding","dc:description":"eIF2B is a decameric, a dimer of eIF2B (beta, gamma, delta, epsilon) tetramers stabilized by 2 copies of eIF2Bα. EIF2B4 is experimentally proven to interact with EIF2B5, which has been established to cause vanishing white matter disease.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24532666","rdfs:label":"Protein Interaction","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3.5},{"id":"https://genegraph.clinicalgenome.org/r/a3c95d30-0045-4bf9-8529-3c701bb1eab5_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/31325a38-6e98-4f7f-a9a0-1988e13dcaf2_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3a538048-7c23-441f-a54b-df62e654cd71","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3a538048-7c23-441f-a54b-df62e654cd71_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Liu et al. 2011 showed variant results in significant decrease in GEF eIF2B activity.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/3a538048-7c23-441f-a54b-df62e654cd71_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14566705","allele":{"id":"https://genegraph.clinicalgenome.org/r/738bc4ee-a68f-4cdc-85ba-c832602b122c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001034116.2(EIF2B4):c.1447C>T (p.Arg483Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA44509202"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/31325a38-6e98-4f7f-a9a0-1988e13dcaf2","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14566705","rdfs:label":"Case 4","ageType":"AgeAtDeath","ageUnit":"Months","ageValue":42,"allele":{"id":"https://genegraph.clinicalgenome.org/r/738bc4ee-a68f-4cdc-85ba-c832602b122c"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0000252","obo:HP_0000741","obo:HP_0002352","obo:HP_0011968","obo:HP_0001347","obo:HP_0002104","obo:HP_0002013","obo:HP_0008936","obo:HP_0002509","obo:HP_0001250"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/3a538048-7c23-441f-a54b-df62e654cd71_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/5214b34c-8eb1-4119-9cb3-ab102d16daf3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/029ef461-de32-451f-8add-495a1ed0ff0a","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/029ef461-de32-451f-8add-495a1ed0ff0a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Liu et al. 2011 showed variant results in significant decrease in GEF eIF2B activity.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/029ef461-de32-451f-8add-495a1ed0ff0a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15136673","allele":{"id":"https://genegraph.clinicalgenome.org/r/d1ea5fe4-81e4-429c-8936-da69cc0ba00d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001034116.2(EIF2B4):c.1069C>T (p.Arg357Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1576662"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/5214b34c-8eb1-4119-9cb3-ab102d16daf3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15136673","rdfs:label":"833","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":18,"allele":{"id":"https://genegraph.clinicalgenome.org/r/d1ea5fe4-81e4-429c-8936-da69cc0ba00d"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0002352","obo:HP_0001270","obo:HP_0004302"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/029ef461-de32-451f-8add-495a1ed0ff0a_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/a3cc10c0-2915-4b4d-83d0-fb0cb3662d41_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/22ec3a98-f490-41a8-95ab-1768592cc9de","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/22ec3a98-f490-41a8-95ab-1768592cc9de_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Fogli et al. 2004 show GEF eIF2B activity in lymphocytes are decreased compared to healthy controls.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/22ec3a98-f490-41a8-95ab-1768592cc9de_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15136673","allele":{"id":"https://genegraph.clinicalgenome.org/r/3e1fc36a-acaf-41fd-8895-1ff3fd257f85","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001034116.2(EIF2B4):c.626G>A (p.Arg209Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1576829"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/a3cc10c0-2915-4b4d-83d0-fb0cb3662d41","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15136673","rdfs:label":"570-1††","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":30,"allele":{"id":"https://genegraph.clinicalgenome.org/r/3e1fc36a-acaf-41fd-8895-1ff3fd257f85"},"firstTestingMethod":"PCR","phenotypes":"obo:HP_0002352","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/22ec3a98-f490-41a8-95ab-1768592cc9de_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/94954986-1830-4e84-b109-acd387df2385_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b6459659-d292-4968-9e97-a8ea27473b53","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b6459659-d292-4968-9e97-a8ea27473b53_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Fogli et al. 2004 show GEF eIF2B activity in lymphocytes are decreased compared to healthy controls.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/b6459659-d292-4968-9e97-a8ea27473b53_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15136673","allele":{"id":"https://genegraph.clinicalgenome.org/r/7172b4d0-d707-49be-8288-0e526e8b9863","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001034116.2(EIF2B4):c.728C>T (p.Pro243Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1576800"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/94954986-1830-4e84-b109-acd387df2385","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15136673","rdfs:label":"359","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":6,"allele":{"id":"https://genegraph.clinicalgenome.org/r/7172b4d0-d707-49be-8288-0e526e8b9863"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0004302","obo:HP_0000750","obo:HP_0002352"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/b6459659-d292-4968-9e97-a8ea27473b53_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/48c73377-c7b7-46ce-acd7-deb12563f899_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11293815-9f86-4546-a86c-d73816dc8642","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11293815-9f86-4546-a86c-d73816dc8642_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11835386","allele":{"id":"https://genegraph.clinicalgenome.org/r/a18244c5-e7cd-4f1e-a297-5dcf7fe3107c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001034116.2(EIF2B4):c.683C>T (p.Ala228Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340164"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/4504c5d1-7aee-4467-8a2d-61b0fb0a7b3e","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4504c5d1-7aee-4467-8a2d-61b0fb0a7b3e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11835386","allele":{"id":"https://genegraph.clinicalgenome.org/r/6b83bb19-062f-4df8-8d73-1201b2285753","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001034116.2(EIF2B4):c.1191+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340163"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/48c73377-c7b7-46ce-acd7-deb12563f899","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11835386","rdfs:label":"vwm244","allele":[{"id":"https://genegraph.clinicalgenome.org/r/a18244c5-e7cd-4f1e-a297-5dcf7fe3107c"},{"id":"https://genegraph.clinicalgenome.org/r/6b83bb19-062f-4df8-8d73-1201b2285753"}],"firstTestingMethod":"PCR","phenotypeFreeText":"This patient is part of original cohort published by Dr. van der Knaap. This patient fulfilled MRI criteria: (1) the cerebral hemispheric white matter is symmetrically and diffusely abnormal; (2) part or all of the abnormal white matter has a signal intensity close to or the same as CSF on both T2-weighted and either proton density or fluid-attenuated inversion recovery (FLAIR) images; (3) a fine meshwork of remaining tissue strands is visible within the areas of CSF-like white matter, with a typical radiating appearance on sagittal and coronal images and a dotlike pattern in the centrum semiovale on the transverse images.","phenotypes":"obo:HP_0002352","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/4504c5d1-7aee-4467-8a2d-61b0fb0a7b3e_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/11293815-9f86-4546-a86c-d73816dc8642_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/31bb5b1b-1a51-4dc2-9a73-a946484b3bdb_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7adda104-7dcc-4e7d-8bec-2bdee46ed53b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7adda104-7dcc-4e7d-8bec-2bdee46ed53b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Fogli et al. 2004 show GEF eIF2B activity in lymphocytes are decreased compared to healthy controls.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/7adda104-7dcc-4e7d-8bec-2bdee46ed53b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22128017","allele":{"id":"https://genegraph.clinicalgenome.org/r/3e1fc36a-acaf-41fd-8895-1ff3fd257f85"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ca11dbb9-95c4-487f-a72d-719deb4477e6","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ca11dbb9-95c4-487f-a72d-719deb4477e6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22128017","allele":{"id":"https://genegraph.clinicalgenome.org/r/beb03f2e-5423-4279-bf42-1f4b735f1247","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001034116.2(EIF2B4):c.625C>T (p.Arg209Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA44512958"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/31bb5b1b-1a51-4dc2-9a73-a946484b3bdb","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22128017","rdfs:label":"B","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":14,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/3e1fc36a-acaf-41fd-8895-1ff3fd257f85"},{"id":"https://genegraph.clinicalgenome.org/r/beb03f2e-5423-4279-bf42-1f4b735f1247"}],"detectionMethod":"Not specified in paper.","phenotypeFreeText":"Symptoms provoked by traumatic event.","phenotypes":["obo:HP_0002061","obo:HP_0000529","obo:HP_0002352","obo:HP_0002066"],"sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/ca11dbb9-95c4-487f-a72d-719deb4477e6_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/7adda104-7dcc-4e7d-8bec-2bdee46ed53b_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/4bb1e5a6-3acf-4e1f-9867-cd3c19bd7bec_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/53d9dccc-9f41-4fb0-9925-757fe4f046ef","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/53d9dccc-9f41-4fb0-9925-757fe4f046ef_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22128017","allele":{"id":"https://genegraph.clinicalgenome.org/r/96c259e4-17d4-45e6-a7a4-bb4e36cd6c03","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001034116.2(EIF2B4):c.1399C>T (p.Arg467Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1576579"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/df711b7c-9545-41d1-b820-5d8ef6a7bddc","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/df711b7c-9545-41d1-b820-5d8ef6a7bddc_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Fogli et al. 2004 show GEF eIF2B activity in lymphocytes are decreased compared to healthy controls.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/df711b7c-9545-41d1-b820-5d8ef6a7bddc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22128017","allele":{"id":"https://genegraph.clinicalgenome.org/r/3e1fc36a-acaf-41fd-8895-1ff3fd257f85"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/4bb1e5a6-3acf-4e1f-9867-cd3c19bd7bec","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22128017","rdfs:label":"F","ageType":"AgeAtReport","ageUnit":"Years","ageValue":29,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/3e1fc36a-acaf-41fd-8895-1ff3fd257f85"},{"id":"https://genegraph.clinicalgenome.org/r/96c259e4-17d4-45e6-a7a4-bb4e36cd6c03"}],"detectionMethod":"Not specified in paper.","phenotypeFreeText":"Symptoms provoked by traffic accident.","phenotypes":["obo:HP_0006986","obo:HP_0002061","obo:HP_0001260","obo:HP_0002352"],"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/df711b7c-9545-41d1-b820-5d8ef6a7bddc_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/53d9dccc-9f41-4fb0-9925-757fe4f046ef_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.6},{"id":"https://genegraph.clinicalgenome.org/r/17752528-8acb-4c17-a80b-2b4bdadd3f03_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6fd00da7-f7dc-4fb9-abe4-5080930c84d5","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6fd00da7-f7dc-4fb9-abe4-5080930c84d5_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Fogli et al. 2004 show GEF eIF2B activity in lymphocytes are decreased compared to healthy controls.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/6fd00da7-f7dc-4fb9-abe4-5080930c84d5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15136673","allele":{"id":"https://genegraph.clinicalgenome.org/r/7172b4d0-d707-49be-8288-0e526e8b9863"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/17752528-8acb-4c17-a80b-2b4bdadd3f03","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15136673","rdfs:label":"949","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":54,"allele":{"id":"https://genegraph.clinicalgenome.org/r/7172b4d0-d707-49be-8288-0e526e8b9863"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0002352","obo:HP_0004302"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/6fd00da7-f7dc-4fb9-abe4-5080930c84d5_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":9.2}],"evidenceStrength":"Definitive","sequence":9501,"specifiedBy":"GeneValidityCriteria11","strengthScore":12.7,"subject":{"id":"https://genegraph.clinicalgenome.org/r/GzPe2EWc0sg","type":"GeneValidityProposition","disease":"obo:MONDO_0957872","gene":"hgnc:3260","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_a3c95d30-0045-4bf9-8529-3c701bb1eab5-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}